RP400c synthetic peptide: Began Phase I trial

Repligen Corp. (RGEN) Product: RP400c synthetic peptide based on the V3 loop of HIV Indication: Therapeutic vaccine in asymptomatic HIV-positive patients Status: Began Phase I trial ...